Novartis PREVENT data shows Cosentyx helps patients realize early and lasting relief in axial spondyloarthritis.

Novartis, announced the full 52-week results from the Phase III PREVENT trial, which reinforce the substantial and sustained benefits of Cosentyx (secukinumab) across the axial spondyloarthritis (axSpA) spectrum . The study found patients treated with Cosentyx 150 mg showed significant and sustained improvements in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) at 52 weeks. nr-axSpA is a painful and debilitating condition affecting 1.7 million people in the top five EU countries and the US2. However, because nr-axSpA is underdiagnosed, with an average delay in diagnosis of more than seven years, that number may be higher. The PREVENT trial met its primary endpoint of 40% improvement in the Assessment of Spondyloarthritis International Society (ASAS40) in biologic treatment-naïve patients at Week 16 and Week 52 versus placebo (41.5% vs 29.2%: P<0.05 and 35.4% vs 19.9%: p><0.05), respectively when a loading dose was used. secondary endpoints indicating improvements in pain, mobility and health-related quality of life were also met in the trial up to week 52. the trial demonstrated a safety profile consistent with previous clinical trials with no new safety signals reported1. the prevent data are being presented at the annual european congress of rheumatology (eular) e-congress 2020. cosentyx is the first fully-human interleukin (il)-17a inhibitor indicated for patients in europe with nr-axspa and is backed by five years of clinical data supporting long-term safety and efficacy across moderate-to-severe plaque psoriasis (pso), psoriatic arthritis (psa) and ankylosing spondylitis (as).>